Another Oral GlyT1 Inhibitor Meets a Familiar End
This article covers the discovery, development, and Phase III failure of iclepertin, detailing its structure, pharmacology, clinical journey, and the challenges of GlyT1-targeted therapies.
Read more:
drughunters.com/43TctNC